Genomes exhibit resistance development in Klebsiella pneumoniae isolates, indicating treatment challenges with emerging resistance.
Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp) are high-priority pathogens. Although meropenem/vaborbactam is a preferred treatment, resistance can emerge. Two KPC-Kp isolates from the Centers for Disease Control and Prevention(CDC) Antimicrobial Resistance Isolate Bank were sequenced before and after development of meropenem/vaborbactam resistance following treatment with this antibiotic in the hollow fiber infection model (HFIM).
No takes yet. Share an insight, caveat, or question.
Ozer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: